This week, Clinical Trials Arena will be shining a spotlight on precision medicine and biomarkers as part of April’s ‘Precision Medicine Week’. Running throughout the week of April 24, 2017, CTA will post articles uncovering the most pressing issues facing industry today surrounding personalized medicine and biomarker development.
Experts, such as, Jane Rhodes of Biogen, shine a spotlight on the role digital biomarkers can play in clinical research. Meanwhile, CTA Editor, Henry Kerali speaks to an industry expert who explains how the use of precision medicine can be implemented as a business model.
But first, be sure to visit CTA tomorrow when Oliver Chao of Sanofi explores the ‘chronobiome,’ which he believes could be key to realizing the potential of precision medicine.
In the meantime, catch up on some CTA’s most recent stories delving into the challenges of precision medicine and biomarker development… (click on the headline to finish reading).
Over the past 20 years since the Human Genome Project was initiated, precision medicine has come to prominence in the clinical trial space. In the early 90s, genomics came to the fore as a discipline, and served as a precursor to the shift towards pharmcogenomics in the late 90s/early 00s.
In recent times, there has been a clamor towards personalized medicine, a form of treatment that's tailored toward a person based on a number of factors: their genes, proteins and their environment. In cancer, "personalized medicine uses specific information about a person’s tumor to help diagnose, plan treatment, find our how well a treatment is working, or make a prognosis," according to the National Cancer Institute (NCI). Even the term ‘personalized medicine’ has taken many guises in the form of targeted medicine, stratified medicine, before evolving into what is now commonly termed precision medicine.
Management of Specimens collected in Biomarker-driven Clinical Trials: Integration of Datasets to drive Translational Science
Recent progress in translational and personalized medicine initiatives has created a new landscape with the requirement for innovative ways to manage clinical specimens collected in global biomarker driven trials. With such advancements, many have seen a shift in expectations from the classical bench-to-bedside approach, to one that integrates bedside-to-bench information. To truly fulfill the promise of personalized medicine, we need to incorporate, in real time, specimen metadata, clinical information, and molecular data from a trial to execute translational science. In the past, specimens were often collected from clinical trial participants, stored in a biorepository, and accessed at some later point long after the trial was completed.